CD88 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
C5a Receptor Antagonist, W-54011 | 405098-33-1 | sc-203863 sc-203863A | 1 mg 5 mg | $206.00 $645.00 | 7 | |
C5a Receptor Antagonist, W-54011, selectively inhibits the C5a receptor, disrupting the complement system's signaling pathways. Its unique molecular structure facilitates high-affinity binding, preventing C5a from activating downstream inflammatory responses. The compound's interaction with the receptor alters conformational dynamics, influencing receptor desensitization and internalization processes. This modulation can significantly impact cellular responses to inflammatory stimuli, highlighting its role in immune regulation. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, which can indirectly affect CD88 activity by modulating T-cell activation and cytokine production, processes that can regulate CD88 expression. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A phosphodiesterase-4 inhibitor, Rolipram increases cAMP levels, which can suppress the expression of pro-inflammatory cytokines, indirectly inhibiting CD88 expression and activation. | ||||||
SB 290157 trifluoroacetate salt | 1140525-25-2 | sc-222291 sc-222291A sc-222291B | 10 mg 50 mg 100 mg | $166.00 $624.00 $1040.00 | 10 | |
SB 290157 trifluoroacetate salt acts as a non-peptide antagonist of CD88, competitively inhibiting its activation by C5a and reducing downstream inflammatory responses mediated by CD88. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
A glucocorticoid that inhibits NF-κB signaling, Dexamethasone can reduce the expression of inflammatory mediators and receptors, including CD88, by suppressing pro-inflammatory pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin can downregulate immune responses, potentially leading to decreased expression or activity of CD88, as it is involved in immune cell signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY294002, can affect CD88 signaling by altering PI3K-dependent pathways that are involved in CD88-mediated cell responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As a MEK inhibitor, PD98059 can affect the MAPK/ERK pathway, which is involved in CD88 signaling, potentially reducing CD88-mediated responses in immune cells. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, it can indirectly affect CD88 activity, as PI3K is involved in the signaling pathways activated by CD88. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can modulate signaling pathways downstream of CD88, potentially reducing the receptor's ability to mediate inflammatory responses. | ||||||